Recent News for OVID - Ovid Therapeutics Inc.

Date Title
Dec 28 The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO
Dec 25 How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?
Dec 21 The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
Dec 17 Ovid's OV935 shows positive action in epilepsy study; shares up 1%
Dec 17 Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
Dec 14 The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
Dec 13 The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Dec 12 The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
Dec 6 Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
Dec 6 The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering
Dec 6 50 Biggest Movers From Tuesday
Nov 28 The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings
Nov 16 Granite Point Capital’s Returns, AUM, and Holdings
Nov 15 Raymond James likes Galapagos in premarket analyst action
Nov 15 The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Nov 14 Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
Nov 8 Ovid Therapeutics reports Q3 results
Nov 8 Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress
Oct 31 The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
Oct 25 Ovid to host CC on new data on OV101 in Angelman syndrome
Oct 25 Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting
Oct 22 Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community
Oct 22 Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT
Oct 19 Key events next week - healthcare

Back to the Main OVID Page...